Global Staphylococcal Infection Drugs Market 2019-2023

About this market

Regulatory agencies are granting special drugs designations for the development of drugs for the treatment of infectious diseases, including those used for the treatment of staphylococcal infection. Special drug designations offer incentives for the development of new drugs for the treatment which is encouraging more and more manufacturers to invest in the development of drugs, which in turn is driving the market. The analysts have predicted that the staphylococcal infection drugs market will register a CAGR of nearly 3% by 2023.

Market Overview

Increasing incidence of staphylococcal infections

The emergence of antibiotics resistant strains has led to increased incidence of staphylococcal infections. Skin and soft tissue infections are the most common type of infections caused by staphylococcal. Thus, rising incidence of staphylococcal infections is a major driver contributing to the market growth.

Lack of vaccines and new drug classes

Unlike most of the infectious diseases that can be prevented by vaccines, there is no approved vaccine for the prevention of staphylococcal infections. The rapid evolution of the bacteria responsible along with the following factors pose a major hurdle to the development of vaccines against staphylococcal infections.

For the detailed list of factors that will drive and challenge the growth of the staphylococcal infection drugs market during the 2019-2023, view the full report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Merck & Co. Inc. and Pfizer Inc the competitive environment is quite intense. Factors such as the increasing incidence of staphylococcal infections and special drug designations, will provide considerable growth opportunities to staphylococcal infection drugs manufactures. Allergan Plc, Bayer AG, GlaxoSmithKline Plc, Merck & Co. Inc., and Pfizer Inc. are some of the major companies covered in this report.

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

Preface
Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem
Market characteristics
Market segmentation analysis

PART 04: MARKET SIZING

Market definition
Market sizing 2018
Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product
Comparison by product
Beta-lactams - Market size and forecast 2018-2023
Peptides - Market size and forecast 2018-2023
Quinolones - Market size and forecast 2018-2023
Macrolides - Market size and forecast 2018-2023
Others - Market size and forecast 2018-2023
Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation
Geographic comparison
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Key leading countries
Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers
Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

Overview
Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered
Vendor classification
Market positioning of vendors
Allergan Plc
Bayer AG
GlaxoSmithKline Plc
Merck & Co. Inc.
Pfizer Inc.

PART 14: APPENDIX

Research methodology
List of abbreviations
Definition of vendors classification

List of Exhibits

Exhibit 01: Global infectious disease treatment market
Exhibit 02: Segments of global infectious disease treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Beta-lactams - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Beta-lactams - Year-over-year growth 2019-2023 (%)
Exhibit 21: Peptides - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Peptides - Year-over-year growth 2019-2023 (%)
Exhibit 23: Quinolones - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Quinolones - Year-over-year growth 2019-2023 (%)
Exhibit 25: Macrolides - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Macrolides - Year-over-year growth 2019-2023 (%)
Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Others - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by product
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Asia
Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in ROW
Exhibit 39: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: North America - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in North America
Exhibit 42: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 43: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 44: Top 3 countries in Europe
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: Allergan Plc - Vendor overview
Exhibit 54: Allergan Plc - Business segments
Exhibit 55: Allergan Plc - Organizational developments
Exhibit 56: Allergan Plc - Geographic focus
Exhibit 57: Allergan Plc - Segment focus
Exhibit 58: Allergan Plc - Key offerings
Exhibit 59: Bayer AG - Vendor overview
Exhibit 60: Bayer AG - Business segments
Exhibit 61: Bayer AG - Organizational developments
Exhibit 62: Bayer AG - Geographic focus
Exhibit 63: Bayer AG - Segment focus
Exhibit 64: Bayer AG - Key offerings
Exhibit 65: GlaxoSmithKline Plc - Vendor overview
Exhibit 66: GlaxoSmithKline Plc - Business segments
Exhibit 67: GlaxoSmithKline Plc - Organizational developments
Exhibit 68: GlaxoSmithKline Plc - Geographic focus
Exhibit 69: GlaxoSmithKline Plc - Segment focus
Exhibit 70: GlaxoSmithKline Plc - Key offerings
Exhibit 71: Merck & Co. Inc. - Vendor overview
Exhibit 72: Merck & Co. Inc. - Business segments
Exhibit 73: Merck & Co. Inc. - Organizational developments
Exhibit 74: Merck & Co. Inc. - Geographic focus
Exhibit 75: Merck & Co. Inc. - Segment focus
Exhibit 76: Merck & Co. Inc. - Key offerings
Exhibit 77: Pfizer Inc. - Vendor overview
Exhibit 78: Pfizer Inc. - Business segments
Exhibit 79: Pfizer Inc. - Organizational developments
Exhibit 80: Pfizer Inc. - Geographic focus
Exhibit 81: Pfizer Inc. - Segment focus
Exhibit 82: Pfizer Inc. - Key offerings
Exhibit 83: Validation techniques employed for market sizing
Exhibit 84: Definition of vendors classification

Executive Summary

Global Staphylococcal Infection Drugs Market 2019-2023

The author of the report recognizes the following companies as the key players in the global staphylococcal infection drugs market: Allergan Plc, Bayer AG, GlaxoSmithKline Plc, Merck & Co. Inc., and Pfizer Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the expanding R&D of novel therapies.”

According to the report, one of the major drivers for this market is the increasing incidence of staphylococcal infections.

Further, the report states that one of the major factors hindering the growth of this market is the lack of vaccines and new drug classes.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.